Receptor News and Research

RSS

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world.

9 Jul 2021

Metabolites of intestinal bacteria can positively influence the efficacy of tumor therapies

Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from Würzburg and Marburg reveals. The findings could help improve cancer therapies.

9 Jul 2021

Antiviral activity of long-chain polyphosphates against SARS-CoV-2 infection

A new study has been published in Science Signaling that has examined the potential role that long-chain inorganic polyphosphates (polyPs) play against SARS-CoV-2 infection.

9 Jul 2021

New York City SARS-CoV-2 breakthrough cases predominantly Alpha and Iota variants

While Delta (B.1.617.2) has overtaken Alpha (B.1.1.7) as the dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in the United States, Alpha remained a force to be reckoned with in New York City earlier this year. New research published on the preprint medRxiv* server details breakthrough infections in vaccinated and unvaccinated individuals living in New York City.

9 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Early B cell signatures predict antibody responses to mRNA-based COVID-19 vaccine

Researchers in the United States have identified both antigen-specific and antigen non-specific predictive signatures of antibody responses to Moderna’s two-dose coronavirus disease 2019 (COVID-19) vaccine that protects against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

A new article has been published in Cellular and Molecular Lifesciences, which focuses on the connection between host factors and the worsening of the COVID-19. Further, the impact of the virus on the host’s microbiome and secondary infection has also been studied.

8 Jul 2021

Growing concern over SARS-CoV-2 Lambda variant

A new report from Chile – currently available on the medRxiv* preprint server – reveals how mutations in the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lambda variant can confer protection from neutralizing antibodies and increase viral infectivity rates, which means massive vaccination campaigns should be accompanied by strict genomic surveillance.

8 Jul 2021

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Researchers in Germany have provided evidence that a booster shot of a messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine following prime immunization with AstraZeneca’s adenoviral vector-based vaccine is sufficient to achieve high levels of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

How SARS-CoV-2 has evolved over the course of the pandemic

In an effort to understand the ongoing evolution of the SARS-CoV-2 genome, researchers constructed a phylogenetic tree of all available SARS-CoV-2 genomes.

7 Jul 2021

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

A new paper discusses an intriguing new mechanism of immune evasion traceable to specific mutations in the B.1.427/B.1.429 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2021

Common anti-coagulant drug could treat emerging variants of SARS-CoV-2

QUT PhD researcher Zachariah Schuurs said the research team had identified a new binding site on the SARS-CoV-2 spike protein.

7 Jul 2021

Can memory T cell responses to seasonal coronaviruses protect against severe COVID-19?

In a recent study published in the journal Science Immunology, scientists have revealed that the presence of CD8+ T cells against conserved epitopes of seasonal coronaviruses is associated with mild coronavirus disease 2019 (COVID-19). These immune cells exhibit a memory phenotype and provide protection against severe disease.

7 Jul 2021

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Researchers examined cases of SARS-CoV-2 infection in fully and partially vaccinated healthcare workers, finding that vaccination provided strong immunity to the virus even though VOCs are on the rise in the non-vaccinated community at large.

7 Jul 2021

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Together with their multifaceted action mechanisms, activation-induced cytidine deaminase (AID) and so-called APOBEC proteins are important factors in the body's immune response and offer fast and effective protection against a large number of DNA and RNA viruses.

7 Jul 2021

Study identifies specialized immune cells that sculpt inhibitory neurons to regulate brain wiring

From the bark of a puppy to the patter of rain against the window, our brains receive countless signals every second. Most of the time, we tune out inconsequential cues--the buzz of a fly, the soft rustle of leaves in the tree--and pay attention to important ones--the sound of a car horn, a bang on the door.

7 Jul 2021

University of Liverpool signs option agreement with BARD1 for type 3C diabetes test

The University of Liverpool has signed a two year option agreement with the Australian diagnostics company, BARD1 Life Sciences Ltd (ASX: BD1), for a type 3c diabetes (T3cDM) blood test. The test uses patented technology developed by researchers in the University of Liverpool's Institute of Systems, Molecular and Integrative Biology.

7 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Jul 2021

Receptor News and Research

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

Metabolites of intestinal bacteria can positively influence the efficacy of tumor therapies

Antiviral activity of long-chain polyphosphates against SARS-CoV-2 infection

New York City SARS-CoV-2 breakthrough cases predominantly Alpha and Iota variants

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Early B cell signatures predict antibody responses to mRNA-based COVID-19 vaccine

How do host factors like the lung microbiome aid in SARS‐CoV‐2 infection?

Growing concern over SARS-CoV-2 Lambda variant

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

How SARS-CoV-2 has evolved over the course of the pandemic

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

Common anti-coagulant drug could treat emerging variants of SARS-CoV-2

Can memory T cell responses to seasonal coronaviruses protect against severe COVID-19?

New study reports low SARS-CoV-2 breakthrough infections in vaccinated healthcare workers

Study addresses potential interrelations between AID/APOBECs and the SARS-CoV-2 virus

Study identifies specialized immune cells that sculpt inhibitory neurons to regulate brain wiring

University of Liverpool signs option agreement with BARD1 for type 3C diabetes test

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News